Complications of androgen-deprivation therapy in men with prostate cancer

被引：23

作者：

Chen A.C. ^{[1
]}

Petrylak D.P. ^{[1
]}

机构：

[1] Department of Medicine, College of Physicians and Surgeons, Columbia University, 177 Fort Washington Avenue, MHB 6-435, New York, 10032, NY

来源：

Current Urology Reports | 2005年 / 6卷 / 3期

关键词：

Advanced Prostate Cancer; Androgen Deprivation Therapy; Prostate Cancer; Prostate Cancer Patient; Zoledronic Acid;

D O I：

10.1007/s11934-005-0009-2

中图分类号：

学科分类号：

摘要：

Androgen-deprivation therapy (ADT) is indicated for the treatment of metastatic prostate cancer and locally advanced disease. In addition to sexual side effects, long-term ADT results in several other changes, including hot flashes; gynecomastia; changes in body composition, metabolism, and the cardiovascular system; osteoporosis; anemia; psychiatric and cognitive problems; and fatigue and diminished quality of life. This review discusses these complications of ADT and treatments aimed at reducing them. It is important for clinicians to anticipate these effects and to initiate measures to prevent or minimize them in order to maintain quality of life in prostate cancer survivors. © 2005, Current Science Inc.

引用

页码：210 / 216

页数：6

共 59 条

[31]

Eriksson S., Eriksson A., Stege R., Et al., Bone mineral density in patients with prostate cancer treated with orchidectomy and with estrogens, Calcif Tissue Int, 57, pp. 97-99, (1995)

[32]

Tyrrell C.J., Blake G.M., Iversen P., Et al., The non-steroidal antiandrogen, bicalutamide (’Casodex’), may preserve bone mineral density as compared with castration: results of a preliminary study, World J Urol, 21, pp. 37-42, (2003)

[33]

Santini D., Gentilucci U.V., Vincenzi B., Et al., The antineoplastic role of bisphosphonates: from basic research to clinical evidence, Ann Oncol, 14, pp. 1468-1476, (2003)

[34]

Saad F., Gleason D.M., Murray R., Et al., A randomized, placebocontrolled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma, J Natl Cancer Inst, 94, pp. 1458-1468, (2002)

[35]

Diamond T.H., Winters J., Smith A., Et al., The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study, Cancer, 92, pp. 1444-1450, (2001)

[36]

Smith M.R., McGovern F.J., Zietman A.L., Et al., Pamidronate to prevent bone loss during androgen deprivation therapy for prostate cancer, N Engl J Med, 345, pp. 948-955, (2001)

[37]

Smith M.R., Eastham J., Gleason D.M., Et al., Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer, J Urol, 169, pp. 2008-2012, (2003)

[38]

Smith M.R., Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma, Cancer, 97, pp. 789-795, (2003)

[39]

Besa E.C., Hematologic effects of androgens revisited: an alternative therapy in various hematologic conditions, Semin Hematol, 31, pp. 134-145, (1994)

[40]

Strum S.B., McDermed J.E., Scholz M.C., Et al., Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade, Br J Urol, 79, pp. 933-941, (1997)

← 1 2 3 4 5 6 →